The global Bleeding Disorders Treatment Market is projected to reach USD 15.09 Billion by 2021 from USD 10.33 Billion in 2016, at a CAGR of 7.9% from 2016 to 2021. The global market is broadly classified into type, drug class, and region.

Based on type, the bleeding disorders treatment market is segmented into hemophilia A, hemophilia B, Von Willebrand Disease (vWD), and others. The hemophilia A segment is projected to register the highest growth rate in the market. Market growth in this market segment is driven by the large number of patients suffering from hemophilia A and rising R&D investment for hemophilia product

Based on class of drug, the bleeding disorders treatment market is segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others. The recombinant coagulation factor concentrates segment is expected to witness the highest growth rate in the market. This growth is attributed to rising R&D activities and increasing focus of pharmaceutical companies on recombinant products resulting in launch of new products.

PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71198026

For the coming five years, APAC and LATAM regions are considered to be the lucrative markets for the bleeding disorders treatment market. Growth in this region can be attributed to increasing initiatives by local governments for increasing access to healthcare, rising disposable income, and increasing focus of global players towards emerging economies.

The key players in the bleeding disorders treatment market are Shire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).